BRAF and triple-negative breast carcinoma: Clinical trials using the WNT pathway inhibitor LGK974 [NCT01351103] alone and in conjunction with anti PD-1 immune checkpoint inhibition in patients with melanoma, B-Raf serine/threonine kinase (BRAF) mutant colorectal cancer and triple negative breast cancer are currently recruiting [126].